Table 2.
Preclinical models of S-AKI and the effect of MSC.
| Team/year | Animal model | Type of MSC/combination | Effect of MSC | Ref. |
|---|---|---|---|---|
| Luo et al. (2014) | CLP-polymicrobial mouse model | Unspecified MSC (1 × 106) | ↓ urea, creatinine ↓ IL-17, CXC, CCL ↓ ATN score |
[41] |
| Cóndor et al. (2016) | CLP-polymicrobial rat | WJ-MSC (1 × 106) | ↑ glomerular filtration (inulin clearance) ↓ apoptosis intensity in the renal parenchyma ↓ kidney infiltration by immunocompetent cells |
[42] |
| Sung et al. (2013) | CLP-polymicrobial mouse model | Apoptotic MSC (1.2 × 106) |
↓ TNF-α ↓ serum creatinine |
[43] |
| Tsoyi et al. (2016) | CLP-polymicrobial mouse (BALB/C) | MSC (2.5–5 × 105) CO preconditioning |
↓ incidence of AKI | [44] |
| Sung et al. (2016) | CLP-polymicrobial mouse model l | A-MSC (5 × 105)/ciprofloxacin (3 mg/kg/5 days) | ↓ expression of proinflammatory cytokines in the kidney | [45] |
| Chen et al. (2014) | CLP-polymicrobial rat | A-MSC (1.2 × 106)/melatonin (20 mg/kg) | ↓ levels of proinflammatory cytokines ↓ expression of NF-κB in the kidney |
[46] |
WJ-MSC = MSC derived from Wharton's jelly; AKI = acute kidney injury; CO = carbon monoxide.